Literature DB >> 20157739

Levels of urinary transforming growth factor beta-1 in children with D+ hemolytic uremic syndrome.

María Gracia Caletti1, Alejandro Balestracci, Adriana Haydeé Roy.   

Abstract

About 25-50% of survivors of the acute phase of postdiarrheal hemolytic uremic syndrome (D+ HUS) develop chronic renal disease. Transforming growth factor beta-1 (TGFbeta-1) is the main fibrogenic growth factor in humans, and there is a significant correlation between its levels and the grade of interstitial fibrosis in chronic nephropathies. We hypothesized that increased urinary TGFbeta-1 may be an early indicator of sequelae in D+ HUS patients who show no sign of renal damage as determined by conventional diagnostic tests. We therefore compared the levels of TGFbeta-1 in urine collected from healthy controls (HC) (n = 18) with that from patients with a past history of D+ HUS (n = 39). We found that TGFbeta-1 excretion was significantly higher (p < 0.001) in the patient group (median level 73 pg/mg creatinine) than in the HC (median level 28 pg/mg creatinine). TGFbeta-1 excretion did not correlate with age, white blood cell count, length of oligoanuric period, maximum creatinine at the acute stage, or length of the follow-up. Since TGFbeta-1 excretion may reflect ongoing renal tissue damage, our results emphasize the need for the lifelong follow-up of patients with a past history of D+ HUS, even those showing apparent recovery. Long-term monitoring of this cohort is necessary to determine the clinical utility of our findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20157739     DOI: 10.1007/s00467-009-1434-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  24 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

2.  Circulating levels of transforming growth factor-beta1 and lymphokines among children with hemolytic uremic syndrome.

Authors:  F Proulx; C Litalien; J P Turgeon; M M Mariscalco; E Seidman
Journal:  Am J Kidney Dis       Date:  2000-01       Impact factor: 8.860

Review 3.  A practical approach to proteinuria.

Authors:  J M Bergstein
Journal:  Pediatr Nephrol       Date:  1999-10       Impact factor: 3.714

Review 4.  Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome.

Authors:  Horatio A Repetto
Journal:  Kidney Int Suppl       Date:  2005-08       Impact factor: 10.545

Review 5.  Transforming growth factor beta in tissue fibrosis.

Authors:  W A Border; N A Noble
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

Review 6.  Renal fibrosis: new insights into the pathogenesis and therapeutics.

Authors:  Youhua Liu
Journal:  Kidney Int       Date:  2006-01       Impact factor: 10.612

7.  Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.

Authors:  Rajiv Agarwal; Senthuran Siva; Stephen R Dunn; Kumar Sharma
Journal:  Am J Kidney Dis       Date:  2002-03       Impact factor: 8.860

8.  Urinary transforming growth factor beta1 in children and adolescents with congenital solitary kidney.

Authors:  Anna Wasilewska; Walentyna Zoch-Zwierz; Katarzyna Taranta-Janusz
Journal:  Pediatr Nephrol       Date:  2008-12-02       Impact factor: 3.714

9.  Long-term follow-up of Argentinean patients with hemolytic uremic syndrome who had not undergone dialysis.

Authors:  Carlos J Cobeñas; Laura F Alconcher; Ana P Spizzirri; Ricardo C Rahman
Journal:  Pediatr Nephrol       Date:  2007-06-13       Impact factor: 3.714

10.  Hemodynamically mediated glomerular injury and the progressive nature of kidney disease.

Authors:  B M Brenner
Journal:  Kidney Int       Date:  1983-04       Impact factor: 10.612

View more
  2 in total

1.  Urinary levels of TGF β-1 and of cytokines in patients with prenatally detected nephrouropathies.

Authors:  Mariana A Vasconcelos; Maria Candida F Bouzada; Katia D Silveira; Leticia R Moura; Fabiana F Santos; Juliana M Oliveira; Flavia F Carvalho; Mauro M Teixeira; Ana Cristina Simões E Silva; Eduardo A Oliveira
Journal:  Pediatr Nephrol       Date:  2011-02-18       Impact factor: 3.714

2.  Urinary Neutrophil Gelatinase-Associated Lipocalin to Monitor Lupus Nephritis Disease Activity.

Authors:  Hani Susianti; Jullyanny W Wijaya; Ati Rastini; Kusworini Handono; Atma Gunawan; Handono Kalim
Journal:  Biomark Insights       Date:  2015-09-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.